KneeVoice, with a valuation of $10 million, is raising funds on MicroVentures. The company is developing a non-invasive device that monitors cartilage degradation in the knees. The platform is being built with neural network, artificial intelligence, and machine learning capabilities and will capture sounds, vibrations, and positions emitted by the knee to monitor the health of knee joints. KneeVoice has filed FDA pre-submission in January 2022 and completed clinical trials in several health centers in the US. Gustavo De Greiff, Felipe Rigby, and Dr. Carlos Leal founded KneeVoice in June 2016. The current crowdfunding campaign has a minimum target of $25,000 and a maximum target of $1,070,000. The campaign proceeds will be used for wearable product development, software, wearable product inventory, diagnostic product inventory, and marketing.